ReviewTranslational oncogenomics2015
Interplay Between Metabolism and Oncogenic Process: Role of microRNAs.
Review in Translational oncogenomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- MiR-106b-5p promotes gastric cancer progression by directly targeting the tumor suppressor RBL2.Scientific reports · 2025Article
- Diet therapy abates mutant APC and KRas effects by reshaping plasma membrane cholesterol nanodomains.Biophysical journal · 2025Article
- Role of Epigenetics for the Efficacy of Cisplatin.International journal of molecular sciences · 2024Review
- A brief glimpse of a tangled web in a small world: Tumor microenvironment.Frontiers in medicine · 2022Review
- Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism.Frontiers in genetics · 2022Review
- Polyunsaturated Fatty Acids Mediated Regulation of Membrane Biochemistry and Tumor Cell Membrane Integrity.Membranes · 2021Review
- Circulating microRNAs modulating glycolysis as non-invasive prognostic biomarkers of HNSCC.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2021Article
- Anti-Angiogenic Effects of Phytochemicals on miRNA Regulating Breast Cancer Progression.Biomolecules · 2020Review
- Circ-ABCB10 Contributes to Paclitaxel Resistance in Breast Cancer Through Let-7a-5p/DUSP7 Axis.Cancer management and research · 2020Article
- A novel 3D in vitro model of glioblastoma reveals resistance to temozolomide which was potentiated by hypoxia.Journal of neuro-oncology · 2019Article
- Reduced Levels of miR-28 and miR-200a Act as Predictor Biomarkers of Aggressive Clinicopathological Characteristics in Gastric Cancer Patients.Galen medical journal · 2019Article
- MicroRNA-130a reduces drug resistance in breast cancer.International journal of clinical and experimental pathology · 2019Article
- Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells.Oncotarget · 2019Article
- Omega-3 fatty acids, membrane remodeling and cancer prevention.Molecular aspects of medicine · 2018Review
- MicroRNA-155-5p suppresses the migration and invasion of lung adenocarcinoma A549 cells by targetingOncology letters · 2018Article
- Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.Oncogene · 2017Article
- Prognostic Implications of miR-302a/b/c/d in Human Gastric Cancer.Pathology oncology research : POR · 2017Article
- miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer.Cell death & disease · 2017Article
- Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance.Human molecular genetics · 2017Article
- Role of microRNA-21 in radiosensitivity in non-small cell lung cancer cells by targeting PDCD4 gene.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is a complex disease that arises from the alterations in the composition and regulation of several genes leading to the disturbances in signaling pathways, resulting in the dysregulation of cell proliferation and death as well as the ability of transformed cells to invade the host tissue and metastasize. It is increasingly becoming clear that metabolic reprograming plays a critical role in tumorigenesis and metastasis. Therefore, targeting this phenotype is considered as a promising approach for the development of therapeutics and adjuvants. The process of metabolic reprograming is linked to the activation of oncogenes and/or suppression of tumor suppressor genes, which are further regulated by microRNAs (miRNAs) that play important roles in the interplay between oncogenic process and metabolic reprograming. Looking at the advances made in the recent past, it appears that the translation of knowledge from research in the areas of metabolism, miRNA, and therapeutic response will lead to paradigm shift in the management of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.